![Simple Western: SREBP1 Antibody [NB100-2215] - Image shows a specific band for SREBP1 in 1 mg/mL of HeLa cell lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Simple-Western-NB100-2215-img0007.jpg "Simple Western: SREBP1 Antibody [NB100-2215] - Image shows a specific band for SREBP1 in 1 mg/mL of HeLa cell lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
| Reactivity | Hu, Mu, Rt, Po, Bv, Ha, Pl, ChHaSpecies Glossary |
| Applications | WB, Simple Western, ICC/IF, IHC, MA |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Format | BSA Free |
| Concentration | 1.0 mg/ml |
| Immunogen | A synthetic peptide made to a portion of the human SREBP1 protein sequence (between residues 300-400). [Uniprot: P36956] |
| Localization | Membranes of ER, Golgi and Cytoplasmic Vesicles. Processed SREBP1 (1-490 a.a.) translocates to the nucleus. |
| Predicted Species | Chinese Hamster (92%). Backed by our 100% Guarantee. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | SREBF1 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||
| Application Notes | Unprocessed SREBP1 is an ~122 kDa integral membrane protein that moves from ER to golgi for processing. The first cleavage is performed by S2P at residue 490, and the resulting active portion is then translocated out of the golgi. This is the ~65 kDa mature form that is detected by NB100-2215. The second cleavage is performed by S1P at residue 530, and the resulting C-term portion (from residues 530-1147) remains in the golgi where it is detected as a ~65 kDa protein by NB100-60545. In Western blot, this SREBP1 antibody detects the processed form of sterol regulatory element-binding protein 1 (aa 1-490) which runs at approx. 65kDa position. In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. Separated by Size-Wes, Sally Sue/Peggy Sue. |
||
| Theoretical MW | 65 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
||
| Control |
|
||
| Control Peptide |
|
||
| Reviewed Applications |
|
||
| Publications |
|
| Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS |
| Preservative | 0.02% Sodium Azide |
| Concentration | 1.0 mg/ml |
| Purity | Immunogen affinity purified |
![Western Blot AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/Akt3_AF887_Western_Blot_5930.jpg)
![Simple Western AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/16332.jpg)
![Intracellular Staining by Flow Cytometry AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/Akt3_AF887_Flow_Cytometry_8283.jpg)
| Images | Ratings | Applications | Species | Date | Details | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Enlarge |
reviewed by:
yuanshu zhang |
WB | Bovine, Mouse, Rat | 03/20/2018 |
Summary
|
||||||||
Enlarge |
reviewed by:
Zachary Patinkin |
Simple Western | Human | 06/14/2015 |
Summary
|
||||||||
|
reviewed by:
Verified Customer |
WB | Mouse | 12/12/2014 |
Summary
|
Secondary Antibodies |
Isotype Controls |
Research Areas for SREBP1 Antibody (NB100-2215)Find related products by research area.
|
|
Metabolic Syndrome: Symptoms and associated disease states By Jamshed Arslan, Pharm. D., PhD. What is metabolic syndrome?It was 1988 when, after decades of research, Dr. GM Reaven of the Stanford University, CA, explained the relationship between four diseases:... Read full blog post. |
|
SREBP2 - regulating cholesterol homeostasis and lipid metabolism Sterol regulatory element-binding proteins (SREBP) are important transcription factors regulating the synthesis and uptake of lipids including cholesterol. This essential role in lipid metabolism makes investigations into the functions SREBPs im... Read full blog post. |
|
SREBP: Gatekeeper of Cholesterol Homeostasis SREBP1 (sterol-regulatory-element-binding protein 2) is a basic-helix-loop-helix-leucine zipper (bHLH-ZIP) transcription factor. It regulates sterol and cholesterol homeostasis by controlling enzymes involved in cholesterol synthesis and uptake, e.g. ... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
5 | |
4 | |
3 | |
2 | |
1 |
| yuanshu zhang 03/20/2018 |
||
| Application: | WB | |
| Species: | Bovine, Mouse, Rat |
| Zachary Patinkin 06/14/2015 |
||
| Application: | Simple Western | |
| Species: | Human |
| Verified Customer 12/12/2014 |
||
| Application: | WB | |
| Species: | Mouse |
| Gene Symbol | SREBF1 |
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-2215] - CDC2 associates with SPDY at ERES. (A-C) 0 h GV stage oocyte labeled for CDC2 (A, green), DNA (A, blue), and SPDY (B, red). Both CDC2 and SPDY localize to the same cortical domain (C). Note that the center of this oocyte is dented (the area that contains the arrow) causing the structure to appear in the middle of the oocyte, whereas it is located in the cortex. Images are Z-projections of 2 (A-C); scale bars represent 20 um in C and 5 um in C'. Arrows indicate the region of the oocyte that is shown enlarged in the insets (B'-C'). Arrowheads denote the position of the GV. Image collected and cropped by CiteAb from the following publication (//bmcdevbiol.biomedcentral.com/articles/10.1186/1471-213X-9-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2215-img0011.jpg "Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-2215] - CDC2 associates with SPDY at ERES. (A-C) 0 h GV stage oocyte labeled for CDC2 (A, green), DNA (A, blue), and SPDY (B, red). Both CDC2 and SPDY localize to the same cortical domain (C). Note that the center of this oocyte is dented (the area that contains the arrow) causing the structure to appear in the middle of the oocyte, whereas it is located in the cortex. Images are Z-projections of 2 (A-C); scale bars represent 20 um in C and 5 um in C'. Arrows indicate the region of the oocyte that is shown enlarged in the insets (B'-C'). Arrowheads denote the position of the GV. Image collected and cropped by CiteAb from the following publication (//bmcdevbiol.biomedcentral.com/articles/10.1186/1471-213X-9-8) licensed under a CC-BY license.")
![Western Blot: SREBP1 Antibody [NB100-2215] - MiR-181a overexpression impairs and miR-181a inhibition improves glucose and lipid homeostasis in HepG2 cellsHepG2 cells were divided into 4 groups as follows: a control group, mimics group (HepG2 cells transfected with 10 nM mimics), NEFA group (treated with 1. 2 mM NEFA), and miR-181a + NEFA group (transfected with 50 nM miR-181a inhibitors and then treated with 1. 2 mM NEFA). It was followed with or without 100 nM insulin. Immunoblot analysis (left) and quantification (right) of SREBP-1c and PPARI+- in HepG2 cells. Image collected and cropped by Citeab from the following publication (Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget (2017)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Western-Blot-NB100-2215-img0010.jpg "Western Blot: SREBP1 Antibody [NB100-2215] - MiR-181a overexpression impairs and miR-181a inhibition improves glucose and lipid homeostasis in HepG2 cellsHepG2 cells were divided into 4 groups as follows: a control group, mimics group (HepG2 cells transfected with 10 nM mimics), NEFA group (treated with 1. 2 mM NEFA), and miR-181a + NEFA group (transfected with 50 nM miR-181a inhibitors and then treated with 1. 2 mM NEFA). It was followed with or without 100 nM insulin. Immunoblot analysis (left) and quantification (right) of SREBP-1c and PPARI+- in HepG2 cells. Image collected and cropped by Citeab from the following publication (Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget (2017)) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-2215] - SREBP1 antibody was tested in HeLa cells with DyLight488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Nuclear and punctate vesicle staining was observed.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2215-img0006.jpg "Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-2215] - SREBP1 antibody was tested in HeLa cells with DyLight488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Nuclear and punctate vesicle staining was observed.")
![Immunohistochemistry-Paraffin: SREBP1 Antibody [NB100-2215] - nalysis of FFPE tissue section of mouse liver with SREBP1 antibody at 1:200. The antibody generated an expected cytoplasmic-nuclear immunostaining of SREBP1 protein in the hepatocytes.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunohistochemistry-Paraffin-NB100-2215-img0008.jpg "Immunohistochemistry-Paraffin: SREBP1 Antibody [NB100-2215] - nalysis of FFPE tissue section of mouse liver with SREBP1 antibody at 1:200. The antibody generated an expected cytoplasmic-nuclear immunostaining of SREBP1 protein in the hepatocytes.")
![Western Blot: SREBP1 Antibody [NB100-2215] - Detection of SREBP1. Lane 1: human liver. Lane 2: mouse liver.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Western-Blot-NB100-2215-img0004.jpg "Western Blot: SREBP1 Antibody [NB100-2215] - Detection of SREBP1. Lane 1: human liver. Lane 2: mouse liver.")
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression impairs & miR-181a inhibition improves glucose & lipid homeostasis in HepG2 cellsHepG2 cells were divided into 4 groups as follows: a control group, mimics group (HepG2 cells transfected with 10 nM mimics), NEFA group (treated with 1.2 mM NEFA), & miR-181a + NEFA group (transfected with 50 nM miR-181a inhibitors & then treated with 1.2 mM NEFA). B was followed with or without 100 nM insulin. (A) Immunoblot analysis (top) & quantification (bottom) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in HepG2 cells. (B) Immunoblotting analysis (top) & quantification (bottom) of insulin-stimulated phosphorylation of AKT in HepG2 cells. (C) Glucose concentration in medium. (D) The glycogen content in HepG2 cells. (E) The mRNA expression levels of G6Pase & PEPCK. (F) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha in HepG2 cells. (G) TG content in HepG2 cells. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682194.jpg "Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression impairs & miR-181a inhibition improves glucose & lipid homeostasis in HepG2 cellsHepG2 cells were divided into 4 groups as follows: a control group, mimics group (HepG2 cells transfected with 10 nM mimics), NEFA group (treated with 1.2 mM NEFA), & miR-181a + NEFA group (transfected with 50 nM miR-181a inhibitors & then treated with 1.2 mM NEFA). B was followed with or without 100 nM insulin. (A) Immunoblot analysis (top) & quantification (bottom) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in HepG2 cells. (B) Immunoblotting analysis (top) & quantification (bottom) of insulin-stimulated phosphorylation of AKT in HepG2 cells. (C) Glucose concentration in medium. (D) The glycogen content in HepG2 cells. (E) The mRNA expression levels of G6Pase & PEPCK. (F) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha in HepG2 cells. (G) TG content in HepG2 cells. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - Effect of restoration of macrophage A2bAR on liver.Liver was collected from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD as described in the methods. Relative mRNA expression was determined using the delta delta CT method with normalization to 18s rRNA. A. mRNA expression of TNF-alpha in liver. A2bAR KO (n = 5) vs WT (n = 7) p-value = 0.0271; A2bAR KO vs CD68-Tg (n = 6) p-value = 0.0210. B. mRNA expression of IL-6 in liver. A2bAR KO (n = 8) vs WT (n = 7) p-value = 0.0159; A2bAR KO vs CD68-Tg (n = 8) p-value = 0.0080. C. mRNA expression of IRS-2 in liver. CD68-Tg (n = 7) vs A2bAR KO (n = 8) p-value = 0.0300. D. Western blot analysis of liver; one representative (of 3 sets) WT, CD68-Tg & A2bAR KO group shown at 15 minutes post-insulin injection, following 16 weeks of HFD. Levels of mature SREBP-1 (68 kDa), & IRS-2 (185 kDa), were probed by Western blot analysis, using beta -actin (43 kDa) as loading control. Quantification of Western Blot results was performed with Image J software (//rsb.info.nih.gov/ij/) with normalization to beta -actin. WT to A2bAR KO: IRS-2 p-value = 0.0092, SREBP-1 p-value = 0.0154; CD68-Tg to A2bAR KO: IRS-2 p-value = 0.0247, SREBP-1 p-value = 0.0170. Data are averages ± SD. *Student two-tail t-test assuming equal variance was found significant only when p-value <0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24892847), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682175.jpg "Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - Effect of restoration of macrophage A2bAR on liver.Liver was collected from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD as described in the methods. Relative mRNA expression was determined using the delta delta CT method with normalization to 18s rRNA. A. mRNA expression of TNF-alpha in liver. A2bAR KO (n = 5) vs WT (n = 7) p-value = 0.0271; A2bAR KO vs CD68-Tg (n = 6) p-value = 0.0210. B. mRNA expression of IL-6 in liver. A2bAR KO (n = 8) vs WT (n = 7) p-value = 0.0159; A2bAR KO vs CD68-Tg (n = 8) p-value = 0.0080. C. mRNA expression of IRS-2 in liver. CD68-Tg (n = 7) vs A2bAR KO (n = 8) p-value = 0.0300. D. Western blot analysis of liver; one representative (of 3 sets) WT, CD68-Tg & A2bAR KO group shown at 15 minutes post-insulin injection, following 16 weeks of HFD. Levels of mature SREBP-1 (68 kDa), & IRS-2 (185 kDa), were probed by Western blot analysis, using beta -actin (43 kDa) as loading control. Quantification of Western Blot results was performed with Image J software (//rsb.info.nih.gov/ij/) with normalization to beta -actin. WT to A2bAR KO: IRS-2 p-value = 0.0092, SREBP-1 p-value = 0.0154; CD68-Tg to A2bAR KO: IRS-2 p-value = 0.0247, SREBP-1 p-value = 0.0170. Data are averages ± SD. *Student two-tail t-test assuming equal variance was found significant only when p-value <0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24892847), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression or SIRT1 knockdown impairs glucose & lipid metabolism in vivo(Aa & Ab) Immunoblotting analysis (left) & quantification (right) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in the liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (B) Glucose tolerance test of mice injected with Ago-181a (n = 7) or Ago-NC (n = 7) or Ad-shRNA NC (n = 6) or Ad-shRNA SIRT1 (n = 6). (C) Insulin tolerance test of mice injected with Ago-181a (n = 7) or Ago-NC (n = 7) or Ad-shRNA NC (n = 6) or Ad-shRNA SIRT1 (n = 6). (D) Representative images of PAS staining (original magnification × 20) of liver sections from mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (Ea & Eb) Immunoblotting analysis (top) & quantification (bottom) of insulin-stimulated phosphorylation of IR, AKT & GSK3 beta in liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (F) Representative images of H&E staining (left, original magnification × 20) & Oil-red staining (right, original magnification × 20) of liver sections from mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (Ga & Gb) Immunoblotting analysis (top) & quantification (bottom) of SREBP-1c & PPAR alpha in the liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241553209.jpg "Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression or SIRT1 knockdown impairs glucose & lipid metabolism in vivo(Aa & Ab) Immunoblotting analysis (left) & quantification (right) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in the liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (B) Glucose tolerance test of mice injected with Ago-181a (n = 7) or Ago-NC (n = 7) or Ad-shRNA NC (n = 6) or Ad-shRNA SIRT1 (n = 6). (C) Insulin tolerance test of mice injected with Ago-181a (n = 7) or Ago-NC (n = 7) or Ad-shRNA NC (n = 6) or Ad-shRNA SIRT1 (n = 6). (D) Representative images of PAS staining (original magnification × 20) of liver sections from mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (Ea & Eb) Immunoblotting analysis (top) & quantification (bottom) of insulin-stimulated phosphorylation of IR, AKT & GSK3 beta in liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (F) Representative images of H&E staining (left, original magnification × 20) & Oil-red staining (right, original magnification × 20) of liver sections from mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (Ga & Gb) Immunoblotting analysis (top) & quantification (bottom) of SREBP-1c & PPAR alpha in the liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression impairs & miR-181a inhibition improves glucose & lipid metabolism in vitro(A, B, C, D & E) Hepatocytes were transfected with 10 nM miR-181a mimics or negative controls in the absence or presence of 100 nM insulin. (A) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta in hepatocytes. (B) The mRNA expression levels of G6Pase & PEPCK in hepatocytes. (C) Glucose concentration in medium. (D) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha expression in hepatocytes. (E) TG content in hepatocytes. (F, G, H, I & J) Hepatocytes were transfected with 50 nM miR-181a inhibitors or negative controls in the absence or presence of 100 nM insulin. (F) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta in hepatocytes. (G) The expression levels of G6Pase & PEPCK in hepatocytes. (H) Glucose concentration in medium. (I) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha expression in hepatocytes. (J) TG content in hepatocytes. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-310202415535169.jpg "Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression impairs & miR-181a inhibition improves glucose & lipid metabolism in vitro(A, B, C, D & E) Hepatocytes were transfected with 10 nM miR-181a mimics or negative controls in the absence or presence of 100 nM insulin. (A) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta in hepatocytes. (B) The mRNA expression levels of G6Pase & PEPCK in hepatocytes. (C) Glucose concentration in medium. (D) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha expression in hepatocytes. (E) TG content in hepatocytes. (F, G, H, I & J) Hepatocytes were transfected with 50 nM miR-181a inhibitors or negative controls in the absence or presence of 100 nM insulin. (F) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta in hepatocytes. (G) The expression levels of G6Pase & PEPCK in hepatocytes. (H) Glucose concentration in medium. (I) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha expression in hepatocytes. (J) TG content in hepatocytes. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - Effect of restoration of macrophage A2bAR on adipose tissue.Visceral (epididymal) adipose tissue was collected from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD as described in the methods. A-C,E. Relative mRNA expression was determined using the delta delta CT method with normalization to 18s rRNA. A. mRNA expression of TNF-alpha in visceral fat. A2bAR KO (n = 7) vs CD68-Tg (n = 9) p-value = 0.0345. B. mRNA expression of IL-6 in visceral fat. A2bAR KO (n = 7) vs WT (n = 7) p-value = 0.0073; A2bAR KO vs CD68-Tg (n = 7) p-value = 0.0141. C. mRNA expression of MCP1 in visceral fat. A2bAR KO (n = 7) vs CD68-Tg (n = 9) p-value = 0.0232. D. Visceral adipose tissue from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD was fixed in 4% paraformaldehyde & paraffin-embedded. Sections immunostained with the macrophage marker F4/80. Representative sections for each genotype at a magnification of 200x & 400x. Arrows point to crown-like structures. E. mRNA expression of IRS-2 in visceral fat. CD68-Tg (n = 8) vs A2bAR KO (n = 8) p-value = 0.0115, WT (n = 6) vs A2bAR KO p-value = 0.0358. F. Western blot analysis of visceral fat; one representative (of 3 sets) WT, CD68-Tg & A2bAR KO group shown at 15 minutes post-insulin injection, following 16 weeks of HFD. WT to A2bAR KO: IRS-2 p-value = 0.0411, SREBP-1 p-value = 0.0103. CD68-Tg to A2bAR KO: IRS-2 p-value = 0.0305, SREBP-1 p-value = 0.0459. Data are averages ± SD. *Student two-tail t-test assuming equal variance was found significant only when p-value <0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24892847), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682189.jpg "Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - Effect of restoration of macrophage A2bAR on adipose tissue.Visceral (epididymal) adipose tissue was collected from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD as described in the methods. A-C,E. Relative mRNA expression was determined using the delta delta CT method with normalization to 18s rRNA. A. mRNA expression of TNF-alpha in visceral fat. A2bAR KO (n = 7) vs CD68-Tg (n = 9) p-value = 0.0345. B. mRNA expression of IL-6 in visceral fat. A2bAR KO (n = 7) vs WT (n = 7) p-value = 0.0073; A2bAR KO vs CD68-Tg (n = 7) p-value = 0.0141. C. mRNA expression of MCP1 in visceral fat. A2bAR KO (n = 7) vs CD68-Tg (n = 9) p-value = 0.0232. D. Visceral adipose tissue from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD was fixed in 4% paraformaldehyde & paraffin-embedded. Sections immunostained with the macrophage marker F4/80. Representative sections for each genotype at a magnification of 200x & 400x. Arrows point to crown-like structures. E. mRNA expression of IRS-2 in visceral fat. CD68-Tg (n = 8) vs A2bAR KO (n = 8) p-value = 0.0115, WT (n = 6) vs A2bAR KO p-value = 0.0358. F. Western blot analysis of visceral fat; one representative (of 3 sets) WT, CD68-Tg & A2bAR KO group shown at 15 minutes post-insulin injection, following 16 weeks of HFD. WT to A2bAR KO: IRS-2 p-value = 0.0411, SREBP-1 p-value = 0.0103. CD68-Tg to A2bAR KO: IRS-2 p-value = 0.0305, SREBP-1 p-value = 0.0459. Data are averages ± SD. *Student two-tail t-test assuming equal variance was found significant only when p-value <0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24892847), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - SIRT1 knockdown impairs & SIRT1 overexpression improves glucose & lipid metabolism in hepatocytes(A) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta protein levels in hepatocytes. Hepatocytes were transfected with SIRT1 siRNA with or without 100 nM insulin. (B) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha protein levels in hepatocytes. Hepatocytes were transfected with SIRT1 siRNA. (C) Immunoblot analysis (left) & quantification (right) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in hepatocytes. Hepatocytes were infected with Ad-SIRT1. (D) Immunoblotting analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, AKT & GSK3 beta in hepatocytes. Hepatocytes were treated with 1.2 mM NEFA or 1.2 mM NEFA & Ad-SIRT1 with or without 100 nM insulin. (E, F & G) Hepatocytes were treated with 1.2 mM NEFA or 1.2 mM NEFA & Ad-SIRT1. (E) Glucose concentration in medium. (F) Immunoblot analysis (top) & quantification (bottom) of SREBP-1c & PPAR alpha in hepatocytes. (G) TG contents in hepatocytes. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-310202415541953.jpg "Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - SIRT1 knockdown impairs & SIRT1 overexpression improves glucose & lipid metabolism in hepatocytes(A) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta protein levels in hepatocytes. Hepatocytes were transfected with SIRT1 siRNA with or without 100 nM insulin. (B) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha protein levels in hepatocytes. Hepatocytes were transfected with SIRT1 siRNA. (C) Immunoblot analysis (left) & quantification (right) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in hepatocytes. Hepatocytes were infected with Ad-SIRT1. (D) Immunoblotting analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, AKT & GSK3 beta in hepatocytes. Hepatocytes were treated with 1.2 mM NEFA or 1.2 mM NEFA & Ad-SIRT1 with or without 100 nM insulin. (E, F & G) Hepatocytes were treated with 1.2 mM NEFA or 1.2 mM NEFA & Ad-SIRT1. (E) Glucose concentration in medium. (F) Immunoblot analysis (top) & quantification (bottom) of SREBP-1c & PPAR alpha in hepatocytes. (G) TG contents in hepatocytes. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunocytochemistry Insulin Antibody (182410) [Unconjugated]](https://images.novusbio.com/images2/Insulin_MAB1417_Immunocytochemistry_9376.jpg)
![Immunohistochemistry Insulin Antibody (182410) [Unconjugated]](https://images.novusbio.com/images2/mab1417_human-bovine-mouse-insulin-mab-clone-182410-immunohistochemistry-308202115145.jpg)
![Immunohistochemistry LDLR Antibody [Unconjugated]](https://images.novusbio.com/images2/LDL_R_AF2255_Immunohistochemistry_7149.jpg)
![Western Blot LDLR Antibody [Unconjugated]](https://images.novusbio.com/images2/LDLR_AF2255_Western_Blot_23731.jpg)
![Western Blot LDLR Antibody [Unconjugated]](https://images.novusbio.com/images/af2255_mouse-ldl-r-affinity-purified-polyclonal-ab-4120241049445.jpg)
![Western Blot SCD-1 Antibody [Unconjugated]](https://images.novusbio.com/images2/SCD-1_AF7550_Western_Blot_12344.jpg)
![Knockout Validated SCD-1 Antibody [Unconjugated]](https://images.novusbio.com/images2/SCD1_AF7550_Knockout_Validated_24050.jpg)
![Knockout Validated SCD-1 Antibody [Unconjugated]](https://images.novusbio.com/images/af7550_human-scd-1-affinity-purified-polyclonal-ab-20820241518560.png)
![N/A Leptin/OB [HRP]](https://images.novusbio.com/images2/Leptin_DLP00_ELISA_134.jpg)
![N/A Leptin/OB [HRP]](https://images.novusbio.com/images2/DATA_Leptin_DLP00_ELISA_749.jpg)
![Immunohistochemistry Lipoprotein Lipase/LPL Antibody [Unconjugated]](https://images.novusbio.com/images2/Lipoprotein_Lipase_AF7197_Immunohistochemistry_21186.jpg)
![Western Blot Lipoprotein Lipase/LPL Antibody [Unconjugated]](https://images.novusbio.com/images2/Lipoprotein_Lipase_AF7197_Western_Blot_11656.jpg)
![Immunocytochemistry Lipoprotein Lipase/LPL Antibody [Unconjugated]](https://images.novusbio.com/images2/Lipoprotein_Lipase_AF7197_Immunocytochemistry_11911.jpg)
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")
